

# Zevalin-BEAM or Zevalin as consolidation in patients with transformed lymphoma.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruiting
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON21852

### Source

NTR

### Health condition

transformed B-cell non-Hodgkin's lymphoma

## Sponsors and support

**Primary sponsor:** VUmc

**Source(s) of monetary or material Support:** initiator=sponsor

## Intervention

## Outcome measures

### Primary outcome

2-year PFS in patients with transformed non-Hodgkin's lymphoma in CR or PR after induction chemotherapy consolidated by 90Yttrium-ibritumomab tiuxetan followed by BEAM and autologous stem cell transplantation or, in patients not eligible for AuSCT, consolidated by a single dose of 90Yttrium-ibritumomab tiuxetan.

### Secondary outcome

1. 2-year OS;

1 - Zevalin-BEAM or Zevalin as consolidation in patients with transformed lymphoma. 5-05-2025

2. Time to next treatment (TTNT);
3. Toxicity in terms of time to recovery of neutrophils and platelets related to previous treatment for indolent or transformed lymphoma;
4. Conversion rate to CR assessed by PET-CT scan after 90Yttrium-ibritumomab tiuxetan (if eligible followed by BEAM and autologous stem cell transplantation) in patients with transformed non-Hodgkin's lymphoma in PET positive PR before consolidation;
5. Reconstitution of immunoglobins and B- and T-cell subsets and NK-cells at different time points after treatment with 90Yttrium-ibritumomab tiuxetan (with or without AuSCT) and monitor the incidence of infections.

## Study description

### Background summary

Study phase:

Phase II clinical trial.

Study objectives:

To estimate 2 year PFS in patients with transformed NHL after consolidation with 90Y ibritumomab tiuxetan-BEAM and AuSCT in patients eligible for AuSCT or after consolidation with a single dose of 90Y ibritumomab tiuxetan in patients not eligible for AuSCT.

Patient population:

Patients with transformed non-Hodgkin's lymphoma in CR or PR after induction/salvage chemotherapy.

Study design:

Phase II prospective cohort study, single center, open label, non-randomized.

Duration of treatment:

Within 3 months of reaching PR or CR after induction therapy, 90Y ibritumomab tiuxetan should be administered, in case of AuSCT followed a week later by BEAM and stem cell transplantation. PET-CT for remission-assessment is done three months and two years after single dose 90Y ibritumomab tiuxetan or AuSCT.

Number of patients:

Z-BEAM followed by AuSCT: 29

90Y ibritumomab tiuxetan single dose: 29.

Adverse events:

1. Length of recovery of neutrophils and platelets;
2. Immune reconstitution.

Start of recruitment: 01-05-2010;

End of recruitment: 01-05-2014.

### **Study objective**

Consolidation of first line treatment of patients with transformed lymphoma with Zevalin of Zevalin-BEAM will prolong PFS.

### **Study design**

End point is progression free survival after 2 years.

### **Intervention**

1. Consolidation of induction chemotherapy in patients eligible for stem cell transplantation with AuSCT preceded by Zevalin-BEAM conditioning;
2. When autologous stem cell transplant is not feasible due to age, comorbidity and/or physical fitness, consolidation of induction chemotherapy in patients with transformed lymphoma not eligible for stem cell transplantation with a single dose (0,4 mCi/kg, max 32 mCi) of 90Y ibritumomab tiuxetan in order to prevent recurrence and prolong PFS.

## Contacts

### Public

VUmc, afdeling hematologie  
de Boelelaan 1117  
M.J. Wondergem  
VUmc, afdeling hematologie  
de Boelelaan 1117  
Amsterdam 1081 HV  
The Netherlands  
+31 (0)20-4442230

### Scientific

VUmc, afdeling hematologie  
de Boelelaan 1117  
M.J. Wondergem  
VUmc, afdeling hematologie  
de Boelelaan 1117  
Amsterdam 1081 HV  
The Netherlands  
+31 (0)20-4442230

## Eligibility criteria

### Inclusion criteria

1. First diagnosis of transformation of lymphoma;
2. Histologically confirmed CD20 positive transformed B cell NHL lymphoma, according to the WHO classification 2008, stage I-IV;
3. For consolidation with AuSCT after Z-BEAM: age 18-66 years old;
4. For single dose 90Y-ibritumomab tiuxetan: older than 65 years and 18-66 years but ineligible for autologous stem cell transplantation;
5. WHO performance status of 0-2 (Appendix C);
6. Life expectancy of at least 3 months;
7. Induction treatment with R-CHOP or R-DHAP-VIM-DHAP;
8. CR defined as disappearance of all evidence of disease on PET-CT or PR defined as a reduction of tumor size of more than 50% and decreasing FDG-avidity on PET-CT after

induction consisting of rituximab containing polychemotherapy. (see appendix A);

9. Absence of PET positive bulky disease after induction treatment defined as a lesion larger than 5 cm;

10. Less than 25% bone marrow involvement at the end of induction treatment (measurement in a representative bone marrow biopsy);

11. For AuSCT: Stem cells harvested: a minimum of  $2 \times 10^6$  CD34+ cells/kg;

12. For single dose  $^{90}\text{Y}$ -ibritumomab tiuxetan: ANC  $\geq 1.5 \times 10^9/\text{l}$  and platelets  $\geq 100 \times 10^9/\text{l}$ ;

13. Written informed consent obtained according to local guidelines.

## **Exclusion criteria**

1. Known hypersensitivity to murine antibodies or proteins;

2. Presence of any other active neoplasms or history of prior malignancy, except non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma during the past 5 years;

3. Patients with abnormal liver function (total bilirubin  $> 2.0 \times \text{ULN}$ );

4. Presence of CNS involvement;

5. Patients with pleural effusion or ascites after induction therapy;

6. Patients who have received G-CSF or GM-CSF therapy within two weeks prior to study enrollment;

7. Patients who have received biologic therapy, immunotherapy, R-CHOP(-like) chemotherapy, surgery, or an investigational drug less than 4 weeks prior to first day of study treatment (i.e.  $^{90}\text{Y}$ trium ibritumomab tiuxetan + AuSCT) or who have not recovered from the toxic effects of such therapy;

8. Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control during study treatment and for at least 12 months thereafter;

9. Known diagnosis of HIV infection;

10. Patients unwilling or unable to comply with the protocol.

Additional exclusion criteria for autologous SCT:

Unfit for high dose chemotherapy followed by autologous stem cell transplantation due to physical or mental condition.

Additional exclusion criteria for single dose 90Y-ibritumomab tiuxetan:

Patients who have received prior external beam radiotherapy to > 25% of active bone marrow (involved field or regional).

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Non-randomized controlled trial
<b>Control:</b>	N/A , unknown

### Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	01-06-2010
Enrollment:	58
Type:	Anticipated

## Ethics review

Positive opinion	
Date:	25-05-2010
Application type:	First submission

## Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL2213
NTR-old	NTR2338
Other	MEtC VUmc : 2010/079
ISRCTN	ISRCTN wordt niet meer aangevraagd.

## Study results

### Summary results

none